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Rapamycin, also known as sirolimus, is an antifungal agent and immunosuppressant
drug used to prevent organ rejection in transplantation. However, little is known about
the role of rapamycin in cardiac hypertrophy and the signaling pathways involved. Here,
the effect of rapamycin was examined using phenylephrine (PE) induced cardiomyocyte
hypertrophy in vitro and in a rat model of aortic banding (AB) - induced hypertrophy
in vivo. Inhibition of MEK/ERK signaling reversed the effect of rapamycin on the
up-regulation of LC3-II, Beclin-1 and Noxa, and the down-regulation of Mcl-1 and
p62. Silencing of Noxa or Beclin-1 suppressed rapamycin-induced autophagy, and
co-immunoprecipitation experiments showed that Noxa abolishes the inhibitory effect
of Mcl-1 on Beclin-1, promoting autophagy. In vivo experiments showed that rapamycin
decreased AB-induced cardiac hypertrophy in a MEK/ERK dependent manner. Taken
together, our results indicate that rapamycin attenuates cardiac hypertrophy by
promoting autophagy through a mechanism involving the modulation of Noxa and
Beclin-1 expression by the MEK/ERK signaling pathway.
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INTRODUCTION
Cardiac hypertrophy is an enlargement of the heart in response to different pathological stimuli
such as hypertension, myocardial ischemia, and endocrine disorders (Frey and Olson, 2003).
Although it is an adaptive response to an increased workload mediated by an increase in muscle
mass to maintain cardiac output, it generally progresses to cardiac remodeling and heart failure and
it is considered a risk factor for cardiovascular disease andmortality (Lips et al., 2003; Li et al., 2015).
The mechanisms underlying cardiac hypertrophy have been investigated to improve the design of
therapeutic strategies for the treatment of heart failure, and recent studies have suggested a link
between autophagy dysregulation and cardiac hypertrophy (Li et al., 2015).
Autophagy, a catabolic process by which cytosolic proteins are degraded in the lysosome, plays
important roles in cellular homeostasis, development, and defense mechanisms (Wang et al., 2009).
Autophagy plays a dual role as a pro- and anti-survival process, and dysregulation of autophagy is
associated with several diseases including cancer, neurodegeneration, and cardiomyopathy (Maiuri
et al., 2007; Levine and Kroemer, 2008). Although autophagy is increased in heart failure associated
with dilated cardiomyopathy, ischemic heart disease, and valvular disease, whether autophagy
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causes heart failure or is activated in response to heart failure
remains unclear (Hein et al., 2003; Li et al., 2014).
Among various pathways known to regulate autophagy
in mammalian cells, the best understood are the class I
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target
of rapamycin (mTOR)/p70 ribosomal protein S6 kinase and
the Ras/Raf-1/mitogen-activated protein kinase ½(MEK1/2)/
extracellular signal-regulated kinase ½(ERK1/2) signaling
pathways (Shinojima et al., 2007). The Akt/mTOR pathway is a
negative regulator of autophagy, whereas the ERK1/2 pathway
positively regulates it. Both class I and class III PI3Ks are
involved in the regulation of autophagy, with class I PI3K playing
an inhibitory role, whereas the class III PI3K complex, which
includes Beclin-1, promotes autophagy (Petiot et al., 2000).
Beclin-1, which was first identified as an interacting partner of
the antiapoptotic protein Bcl-2, is an autophagy related protein
(its yeast homolog is Atg6) that plays a role in the formation of
autophagosomes, which are double-membrane-bound vacuoles
that engulf cellular material targeted for degradation (Liang et al.,
1998; Kihara et al., 2001; Levine and Kroemer, 2008). Autophagy
related genes (Atg) are essential to the process of autophagy
and approximately 30 Atg proteins have been characterized
in yeast and 10 in humans(Mizushima, 2007). Beclin1/Atg6
and microtubule-associated protein 1 light chain 3 (LC3)/Atg8
are among the Atg proteins necessary for autophagosome
formation. During the formation of autophagosomes, cytosolic
LC3-I is conjugated to phosphatidylethanolamine to generate
LC3-II, which is recruited to the autophagosomal membrane
and degraded after the fusion of autophagosomes to lysosomes
(Tanida et al., 2008); therefore, the LC3-II/LC3-I ratio is a
measure of autophagic activity. Oncogenic H-Ras promotes
autophagy by up-regulating Beclin-1 and the Bcl-2 homology-3
(BH3)-only protein Noxa, a pro-apoptotic member of the Bcl-2
family (Elgendy et al., 2011). Binding of Mcl-1 to Beclin-1
interferes with its association with PIK3C3 and inhibits its
autophagy-inducing potential.
Autophagy is induced in eukaryotic cells by starvation, and
the serine/threonine kinase mTOR is a key regulator of the
balance between cell growth and autophagy (Jung et al., 2010).
Rapamycin, a bacterial product and inhibitor of mTOR that is
also known as sirolimus, was developed as a therapeutic agent
because of its immunosuppressant and anti-tumor properties.
Rapamycin binds to mTOR and prevents the phosphorylation
of its downstream substrates p70 ribosomal protein S6 kinase
(P70S6K), eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1) and other proteins involved in transcription,
translation, and cell cycle control and further affecting cell
survival or death (Yang et al., 2015; Zhou et al., 2016). In the
present study, we examined the effect of rapamycin on cardiac
hypertrophy in vitro and in vivo and explored the underlying
mechanisms.
MATERIALS AND METHODS
Reagents
Antibodies were obtained from the following companies:
GAPDH, ERK, p-ERK, MEK, p-MEK, beclin-1, ANP, BNP,
Noxa, LC3-I, LC3-II, Mcl-1, P62, mTOR, p-mTOR, Akt, p-Akt,
P70S6K1, and p-P70S6K1 (Sigma, St. Louis, MO), Rapamycin
and phenylephrine (PE) (Abcam, Cambridge, USA). DMEM
(high glucose) and fetal bovine serum were from Nego
(Shanghai, China). Cell lysis buffer (10×) was obtained from
Cell Signaling Technology (Massachusetts, USA). The RT-PCR
kit was purchased from TOYOBO (Shanghai China). Other
reagents included DAPI (Roche, Germany), hematoxylin and
eosin (H&E, Toronto Chemicals, Toronto, Canada), and trypsin
(Sigma). GFP-LC3 was purchased from Biovector Science Lab,
Inc. (Beijing, China). All pairs of real-time PCR primers
were synthesized by Shenggong Biotechnology (Shanghai,
China). Other chemicals and reagents were of analytical
grade.
Animals and Ethical Statement
Sprague-Dawley rats (8–10 weeks old) were obtained from the
Shanghai SLAC Laboratory Animal Co., Ltd. All animals were
treated in accordance with the Guide for the Care and Use of
Laboratory Animals, and all experiments were approved and
performed following the guidelines of Ruijin Hospital, Minhang
District Central Hospital ethics committee of China.
Cell Lines and Culture Conditions
The H9c2 cell line is a subclone of the original clonal cell line,
which is derived from embryonic rat heart tissue and holds many
cardiomyocyte characteristics. Cells were cultured in Dulbecco’s
Modified Eagle’s medium, supplemented with 10% fetal bovine
serum, 100 U/mL penicillin, and 100 mg/mL streptomycin, at
37◦C in a humidified incubator containing 95% air and 5%
CO2. The media was refreshed every 3 days. Cells cultured
to approximately 80% confluence were treated with either
rapamycin (10 ìM), PE (50 ìM), or PD98059 (2µM; dissolved
in normal saline) alone or in combination under serum-free
conditions.
Western Blot Analysis
H9c2 cells treated as indicated were lysed and approximately
10µg of proteins were separated by SDS-PAGE and
immunoblotted using conventional procedures as described
previously (Cicardo and Dick, 1985). Briefly, the protein samples
extracted from H9c2 cells were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred
to a polyvinylidene difluoride membrane. Membranes were
blocked with TBST containing 5% milk and incubated with the
different primary antibodies as indicated overnight at 4◦C. The
membranes were then incubated with horseradish peroxidase
conjugated secondary antibodies and visualized using the
enhanced chemiluminescence system. Densitometric analysis
was performed using Scion Image software (Scion, Frederick,
MD, USA).
Measurement of the Surface Area of
Cardiomyocytes
The cardiomyocytes were visualized using a charge-coupled
device camera (Olympus, Japan) and analyzed using Image-
Pro Plus software. For measurements of the cell surface
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FIGURE 1 | Effect of phenylephrine on the expression of autophagy and cardiac hypertrophy markers. Cardiomyocytes were incubated in serum-free
medium for 18 h for serum starvation followed by treatment with phenylephrine (PE, 50 ìM) for 6–24 h. (A,B) The expression levels of LC3, Beclin-1, Noxa, Mcl-1, ANP,
BNP, and P62 were examined by western blotting and quantified by densitometry. GAPDH was used as an internal control. Experiments were repeated four times.
*p < 0.05, **p < 0.01, ***p < 0.001 vs. Control treated for 1 h.
area, 100 cells (or myocardial tissue sections) from randomly
selected fields in each group were measured using Image
Pro-Plus 6.0.
Histological Analysis
Hearts were excised, washed with saline solution, and placed in
10% formalin. Hearts were cut transversely close to the apex
to visualize the left and right ventricles. Several sections of the
heart (4–5µm thick) were prepared and stained with H&E for
histopathology and then visualized by light microscopy.
Construction and Infection
For knockdown of MEK, Beclin-1 and Noxa, three small
interfering RNA (siRNA) molecules (siMEK, siBeclin-1 and
siNoxa) were synthesized by GenScript.The target sequences
were 5′-GCCGACTGCAAATACAAGTTT-3′, 5′-GGAGCC
ATTTATTGAAACTTT-3′, and 5′-CCGGAGAATTGGAGA
CAAATT-3′, respectively. H9c2 cells were transfected with
siRNA using the oligofectamine protocol according to the
manufacturer’s instructions (Invitrogen). A GFP-LC3 vector
was used to infect H9c2 cells to monitor puncta formation by
immunofluorescence microscopy using a Fluoview 1000 System
(Olympus, Irving, TX).
RNA Isolation and Semiquantitative
RT–PCR
Total RNA was isolated from various pretreated H9c2 cells using
TRIzol according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). Equal amounts of RNA were added to a reverse
transcriptase reaction mix (Themo Scientific), with oligo-dT
as primer. The resulting templates were subjected to PCR
using the following specific primers: GAPDH (sense 5′-CAT
CTTCTCAAAATTCGAGTGACAA-3′, antisense 5′-AGTAGA
CTCCACGACATACTCA-3′); ANP (sense 5′-CGTATACAG
TGCGGTGTC-3′, antisense 5′-TCCCAGGGGCCGCGCCCG-
3′); BNP (sense 5′-CCAGATGATTCTGCTCCT-3′, antisense
5′-GAATTTCGAAGTCTCTCC-3′); MEK (sense 5′-GGCTTC
TTCCTTCTCGCCCT-3′, antisense 5′-CTTCCAGTTGCAGGG
CACCT-3′); Beclin-1 (sense 5′-CATTACTTACCACAGCCC-3′,
antisense 5′-CATCTGTCTGGCCAGAC-3′); and Noxa (sense 5′-
GAAAGGCGCGTCGGAACG-3′, antisense 5′-TGGGCTTGG
GCTTCTTCT-3′).
Immunoprecipitation
For immunoprecipitation, cells were lysed in IP buffer (20mM
Tris-HCl [pH 7.5], 1mM EDTA, 1M KCl, 5mM MgCl2, 10%
v/v glycerol, 1% v/v Triton X-100, 0.05% v/v 2-Mercaptoethanol
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FIGURE 2 | Effect of rapamycin on the expression of autophagy and cardiac hypertrophy markers. Cardiomyocytes were incubated in serum-free medium
for 18 h followed by treatment with rapamycin (50 ìM) for 6–24 h. (A,B) The expression levels of LC3, Beclin-1, Noxa, Mcl-1, ANP, BNP and P62 were examined by
western blotting and quantified by densitometry. GAPDH was used as an internal control. Experiments were repeated four times. *p < 0.05, **p < 0.01, ***p < 0.001
vs. Control treated for 1 h.
and protease and phosphatase inhibitors). Approximately 1–
4mg of lysate were pre-cleared with protein G beads for
30min at 4◦C and subsequently incubated with antibody pre-
bound to protein G beads for 2–16 h at 4◦C. The beads were
washed three times with NP40 buffer. The immunoprecipitation
beads were mixed with 6 × sample buffer, loaded onto SDS-
PAGE gels, and analyzed by immunoblotting as described
previously.
Autophagy Assay
Autophagy was determined by detection of the processing of the
autophagy marker LC3 and fluorescence microscopic detection
of the formation of the autophagosomes in cells transfected with
GFP-LC3 as described previously (Wang et al., 2009).
Animal Experiments
Cardiac hypertrophy was induced by pressure overload, which
was performed by descending aortic banding (AB). In brief,
rats were maintained in the animal service center of our
institution. Following anesthesia by intraperitoneal injection of
1.5% pentobarbital (W × 0.06), rats had the left thorax opened
at the second intercostal space and a 7-0 silk suture ligature was
tied around the descending aorta against a 26 gauge needle. Then,
the needle was quickly removed. A similar surgery was performed
in the sham-operated mice with the exception of aortic banding.
To study the effect of rapamycin, the mice were intraperitoneally
injected with 0.5mg/kg rapamycin or 0.1mg/kg PD98059 once a
day for 8 weeks. The control mice received an equal volume of
normal saline. Before sacrifice, the mice were anesthetized with
2% isoflurane inhalant.
Echocardiography
The mice were administered inhalant anesthetics (1.5–2%
of isoflurane inhalant mixed with 1 L/min 100% O2) to
ensure that the anesthetic depth was appropriate. Transthoracic
echocardiograms (Visual Sonics Vevo 2100 with a 30-MHz
transducer) were performed by an experienced technologist
blinded to the study group.
Statistical Analysis
Data are expressed as means ± standard deviation (SD) from
at least three independent experiments and were analyzed using
one-way ANOVA and Tukey’s post-hoc test. In all cases, P < 0.05
was considered to be statistically significant.
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FIGURE 3 | Rapamycin induces autophagy via activation of the MEK/ERK pathway. H9C2 cells were treated with rapamycin (10 ìM) for 24 h under conditions
of serum depletion, and then treated with or without the MEK inhibitor PD98059 (2 ìM) for 24 h. (A,B) Constitutive expression of active MEK or ERK triggered
autophagic responses. The expression of the autophagy-related proteins Beclin-1, Noxa, p62 and Mcl-1, and the activation of the MEK/ERK pathway were examined
by western blotting and quantified by densitometry. Data represent the mean of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Control. NS
means no significant differences vs. Control. (C-F) Western blotting and real-time PCR analyses of the relative protein (C) and mRNA (D) levels of MEK in cells treated
with siRNA against MEK. To determine the expression level of the autophagy-related proteins Beclin-1, Noxa, p62 and Mcl-1, H9C2 cells transduced with or without
siRNA against MEK were treated with 10µM rapamycin in serum-free medium for 2 days. Protein expression was examined by western blotting (E) and quantified (F)
by densitometry. Data represent the mean of three independent experiments. **p < 0.01, ***p < 0.001 vs. Control.
RESULTS
PE Induced Cardiomyocyte Hypertrophy
Downregulates Beclin-1 and Noxa
The expression of autophagy related proteins was examined in
a model of PE-induced cardiomyocyte hypertrophy. Treatment
of isolated cardiomyocytes with PE is a method used to
reproduce the features of pathological hypertrophy, such as
increased cell size and sarcomeric re-organization, in vitro
(Taylor et al., 2000). H9c2 cells were incubated in serum-
free medium for 18 h and then treated with or without PE
(50µM) for 6–24 h. Western blot analysis showed that PE
decreased the LC3-II/LC3-I ratio, down-regulated Beclin-1 and
Noxa, and up-regulated p62, Mcl-1 and the cardiomyocyte
hypertrophy markers atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) in a time dependent manner
(Figures 1A,B).
Rapamycin Inhibits Cardiomyocyte
Hypertrophy by Promoting Autophagy
Cardiomyocytes were incubated in serum-free medium for 18 h
and then treated with or without rapamycin (50µM) for 6–24 h.
Western blot analysis showed that rapamycin increased the LC3-
II/LC3-I ratio, up-regulated Beclin-1 and Noxa, down-regulated
p62, and decreased the levels of ANP and BNP and Mcl-1 in a
time dependent manner (Figures 2A,B).
Rapamycin Induced Myocardial Autophagy
in a MEK/ERK Pathway-Dependent Manner
To further examine the mechanism by which rapamycin
attenuates cardiac hypertrophy, H9C2 cells were treated with
or without rapamycin and the MEK inhibitor PD98059, and
the activity of the MEK/ERK1/2 pathway and the expression of
autophagy markers were assessed by western blotting. The results
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FIGURE 4 | The effect of rapamycin induced MEK/ERK mediated autophagy to Akt/mTOR/P70S6K1 pathway. H9C2 cells were treated with rapamycin (10
ìM) for 24 h under conditions of serum depletion, and then treated with or without siRNA against MEK for 24 h. (A,B) The expression of the autophagy-related proteins
Akt, mTOR, P70S6K1, and the phosphorylation activation of the Akt, mTOR, P70S6K1 were examined by western blotting (A) and quantified by densitometry (B).
Data represent the mean of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Control.
FIGURE 5 | Noxa plays an important role in Beclin-1 mediated myocardial autophagy. (A,B) The efficiency of siRNA mediated knockdown of Noxa and
Beclin-1 in H9C2 cells was examined by RT-PCR. (C) The LC3-II/LC3-I ratio and the expression of Mcl-1, p62, Noxa, and Beclin-1 were examined by western blotting
in H9C2 cells transduced with or without siRNA against Noxa or Beclin-1 and treated with 10 ìM rapamycin in serum-free media for 2 days. (D) Quantification of
bands in (C).Data shown are representative of three individual experiments (n = 3, mean ± S.E.M.). *p < 0.05, **p < 0.01, ***p < 0.001 vs. Control. (E) Noxa
promotes autophagy by displacing Mcl-1 from Beclin-1. H9C2 cells transfected with control or siRNA Noxa vector were immunoprecipitated with an anti-Mcl-1
antibody or control IgG and immunoblotted against Beclin-1 and Noxa.
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showed that rapamycin treatment significantly up-regulated
the expression of the phosphorylated forms of MEK and
ERK1/2, up-regulated Beclin-1 and Noxa, and down-regulated
p62 and Mcl-1. These effects were reversed by treatment with
PD98059, indicating that rapamycin induces cardiomyocyte
autophagy through the activation of the MEK/ERK1/2 pathway
(Figures 3A,B). To determine whether the chemical compound
affected the results of the experiment, siRNA against MEK was
constructed. Figures 3C,D shows the effective down-regulation
of MEK at both mRNA and protein levels in response to
siRNA treatment. The same experiments were repeated with
substitution of PD98059 by siMEK under the induction of
rapamycin. The same trend was observed in the results,
indicating no differences between the effects of PD98059 and
siMEK (Figures 3E,F).
Rapamycin Induced MEK/ERK Signaling
Suppressed the Akt/mTOR/P70S6K1
Pathway
We next examined whether activation of the MEK/ERK pathway
induced by rapamycin had an effect on the Akt/mTOR/P70S6K1
pathway (Figures 4A,B). The results showed that inhibition
of MEK by siRNA increased the phosphorylation levels of
both Akt and mTOR. However, the total protein level of
mTOR decreased markedly in the presence of rapamycin. Under
the induction of rapamycin, the phosphorylation level of Akt
increased with or without the down-regulation of MEK. These
results suggested that the Akt mediated pro-survival signaling
pathways mTOR/P70S6K1 were prevented with the inactivation
of mTOR by rapamycin.
Roles of Beclin-1 and Noxa in
Cardiomyocyte Autophagy
The pathway of autophagy in cardiomyocytes was further
examined by siRNA mediated knockdown of Beclin-1 and Noxa
in H9C2 cells. Figures 5A,B shows the effective down-regulation
of Beclin-1 and Noxa in response to siRNA treatment. Silencing
of Beclin-1 significantly decreased the LC3-II/LC3-I ratio and up-
regulated p62 and Mcl-1 in cells exposed to rapamycin, whereas
it had no significant effect on the level of Noxa (Figures 5C,D).
Silencing of Noxa decreased the LC3-II/LC3-I ratio, significantly
up-regulated p62 and Mcl-1, but had no significant effect on
the level of Beclin-1. To understand the roles of Beclin-1 and
Noxa on cardiomyocyte autophagy, H9C2 cells transfected with
control siRNA or siRNA against Noxa were immunoprecipitated
with an anti-Mcl-1 antibody. The results showed that Mcl-
1 co-immunoprecipitated with Beclin-1 only when Noxa was
silenced by siRNA, suggesting that Noxa promotes autophagy by
interfering with the Mcl-1/Beclin-1 interaction (Figure 5E).
Rapamycin Inhibits Cardiomyocyte
Hypertrophy by Promoting Autophagy via
the MEK/ERK1/2 pathway
Figure 6A shows representative images of LC3-GFP
immunofluorescent staining of H9C2 cells treated with
rapamycin, PE and PD98059. Rapamycin treatment resulted in a
FIGURE 6 | Rapamycin induced myocardial autophagy protects against
cardiomyocyte hypertrophy. H9C2 cells were treated with rapamycin (10
ìM), PE (50 ìM) or the MEK inhibitor PD98059 (2µM) and cultured in
serum-free media for 2 days. (A) Representative fluorescence microscopy
images of GFP-LC3 transfected cells treated as indicated. (B) Western blot
analysis of the levels of LC3-I, LC3-II, p62, Noxa, Mcl-1 and Beclin-1. (C) Data
shown are representative of three individual experiments. *p < 0.05 vs.
Control. (D,E) The mRNA expression levels of ANP (D) and BNP (E) in
cardiomyocytes treated as indicated were determined by RT-PCR. *p < 0.05,
**p < 0.01, ***p < 0.001 vs. Control. NS means no significant differences vs.
Control. (F) Measurement of myocardial cross-sectional areas in each group.
*p < 0.05, **p < 0.01, ***p < 0.001 vs. Control.
perinuclear punctate pattern of LC3-GFP immunofluorescence
characteristic of autophagosome formation, which changed to a
diffuse pattern in response to PE. Rapamycin reversed the PE-
induced inhibition of autophagy, as illustrated by the perinuclear
punctate fluorescence, and this effect was suppressed by MEK
inhibition, indicating that rapamycin promotes autophagy
via the MEK/ERK1/2 signaling pathway in cardyomyocytes
under conditions of hypertrophy (Figure 6A). Western blot
analysis confirmed these results by showing that PD98059
reversed the rapamycin induced up-regulation of Beclin-1 and
Noxa and LC3-II/LC3-I, whereas it significant up-regulated
the the levels of p62 (Figures 6B,C). Assessment of the mRNA
levels of ANP and BNP by RT-PCR showed that rapamycin
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TABLE 1 | Echocardiographic data showed the effects of rapamycin on myocardial autophagy induced by AB.
AB − − − + + +
rapamycin − + + − + +
PD98059 − − + − − +
Number n = 8 n = 8 n = 8 n = 8 n = 8 n = 8
LVEDd (mm) 3.69± 0.12 3.72±0.24 3.56± 0.18 5.12±0.13** 4.16± 0.21*$ 5.02±0.62**
LVEDs (mm) 2.64± 0.34 2.58±0.26 2.75± 0.12 4.6±0.42** 2.92± 0.38$$ 3.84±0.27*
LVPWd (mm) 0.89± 0.08 0.91±0.14 0.87± 0.08 1.23±0.11* 0.95± 0.45$ 1.18±0.02*
IVSTd (mm) 0.87± 0.05 0.88±0.14 0.85± 0.05 1.12±0.31* 0.96± 0.06$ 1.09±0.04*
EF% 53.6± 4.8 50.9±6.3 54.2± 4.9 35.62±2.5** 47.8± 3.9$$ 39.24±3.1**
AB, LVEDd, left ventricular end-diastolic dimension (diastolic); LVEDs, left ventricular end-systolic dimension (systolic); LVPWd, left ventricular posterior wall (diastolic); IVSTd,
interventricular septum thickness (diastolic); EF, ejection fraction. Data was represented as mean ± SEM, n = 8. *P < 0.05, **P < 0.01 vs. no-treatment groups. $P < 0.05, $$P < 0.01
vs. AB group.
suppressed the PE-induced up-regulation of ANP and BNP, and
this effect was reversed by PD98059, indicating that rapamycin
inhibits cardiomyocyte hypertrophy via the MEK/ERK1/2
pathway (Figures 6D,E). Myocardial cross-sectional area
measurements showed that PE treatment increased myocardial
size, and blocking rapamycin-induced MEK/ERK1/2 pathway by
PD98059 decreased the reduction of myocardial size (Figure 6F).
Taken together, these results suggest that rapamycin inhibits
cardiac hypertrophy by inducing autophagy via theMEK/ERK1/2
pathway.
Rapamycin-Induced Myocardial Autophagy
Protects Against Cardiac Hypertrophy
To verify our results in vivo, cardiac hypertrophy was induced
by AB in rats, followed by treatment with or without rapamycin
and PD98059. Hearts were excised and tissues were processed
for western blotting and H&E staining. Figures 7A,B, which
shows representative hearts and H&E stained sections, indicates
that the effect of rapamycin on attenuating cardiac hypertrophy
is reversed in the presence of PD98059, suggesting that
rapamycin attenuates cardiac hypertrophy via a MEK dependent
mechanism. Rapamycin treatment down-regulated ANP and
BNP, and up-regulated the autophagy markers Beclin-1 and
Noxa in the hearts of AB rats, and these effects were reversed
by MEK inhibition (Figures 7C,D). To confirm that the effect
of PD98059 on suppressing the rapamycin-induced inhibition
of hypertrophy is mediated by autophagy and not by a direct
effect of PD98059, the mRNA levels of ANP and BNP were
examined by Rt-PCR (Figures 7E,F). The results showed that
PD98059 restored ANP and BNP expression down-regulated by
rapamycin. Furthermore, myocardial cross-sectional area and
heart weight measurements showed that PD98059 inhibited
the attenuation of cardiac hypertrophy induced by rapamycin
(Figures 7G,H). Moreover, echocardiography showed that
rapamycin can effectively reduce LVEDd and LVEDs compared
with the AB group, suggesting that rapamycin induced autophagy
can attenuate cardiac dilation. The mice with pressure overload
subjected to rapamycin treatment demonstrated restored
cardiac function in terms of alleviated EF (47.8 vs. 35.62%). In
addition, echocardiography revealed that rapamycin treatment
may relieve left ventricle thickness compared with AB group
and have no significant different compared with no-treatment
group (Table 1). Accordingly, these findings demonstrate that
rapamycin attenuates cardiac hypertrophy and improves cardiac
function, which are effects that may be related to the induction
of autophagy.
Taken together, these results suggest that the protective
effect of rapamycin on cardiac hypertrophy is mediated by
the induction of autophagy via a mechanism involving the
MEK/ERK1/2 signaling pathway.
Figure 8 shows a schematic illustration depicting a proposed
pathway underlying the effect of rapamycin in our model of
cardiac hypertrophy. Rapamycin up-regulates Beclin-1 and Noxa
by activating the MEK/ERK pathway leading to the induction of
autophagy.
DISCUSSION
Autophagy plays an important role in the maintenance of
cardiac function by removing damaged proteins and subcellular
organelles and protecting myocytes under conditions of stress.
However, the role of autophagy in the diseased heart is not
clear, and whether autophagy promotes cardiomyocyte repair
or elimination remains to be determined. In the present study,
we showed that rapamycin attenuates cardiac hypertrophy
by inducing autophagy and elucidated a potential underlying
mechanism involvingMEK/ERK12 signaling and themodulation
of the expression of Noxa and Beclin-1.
Many signaling pathways regulate autophagy and several
of these pathways operate through mTOR, an inhibitor of
autophagy. We showed that rapamycin, an inhibitor of mTOR,
inhibits cardiac hypertrophy, as determined by the down-
regulation of ANP and BNP in cardiomyocytes, and promotes
autophagy via the up-regulation of Beclin-1 and Noxa and the
down-regulation of p62 and Mcl-1, suggesting that rapamycin
exerts a protective effect on cardiomyocytes via the induction
of autophagy. Rapamycin was previously shown to inhibit
cardiac hypertrophy induced by thyroid hormone treatment
or AB (Ha et al., 2005; Kuzman et al., 2007), although the
role of autophagy was not addressed. The role of the 5′-
AMP-activated protein kinase (AMPK)/mTORC1 pathway in the
induction of autophagy in cardiac hypertrophy was reported
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FIGURE 7 | Rapamycin inhibited cardiac hypertrophy in vivo. (A,B) Whole hearts (A) and H&E staining (B) of normal and aortic banding (AB) mice at 8 weeks
post-surgery in the presence or absence of rapamycin and/or PD98059. (C,D) Western blot analysis of the hypertrophy and autophagy markers ANP, BNP, Beclin-1
and Noxa. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Control. Experiments were repeated three times, n = 3. (E,F) The mRNA expression levels of ANP (F) and BNP (E)
in myocardial tissues in each group were measued by Rt-PCR. *p < 0.05, **p < 0.01 vs. Control. (G,H) Measurements of myocardial cross-sectional area and heart
weight/body weight ratio in the response to the indicated treatments. n = 8. *p < 0.05, **p < 0.01 vs. Control.
by Li et al., who showed that AMPK stimulates autophagy by
blocking the mTOR complex mTORC1 in a pressure overload
model of cardiac hypertrophy (Li et al., 2014). However, AMPK
induced autophagy was not mediated by the regulation of
Beclin-1, which differs from the present results. The protective
effects of rapamycin mediated by the induction of autophagy
were demonstrated in mouse models of Huntington’s disease,
in which inhibition of mTOR promoted the degradation of
protein aggregates via autophagy (Ravikumar et al., 2002).
Autophagy was shown to have a cardioprotective effect in a
mouse model of cecal ligation and puncture, where rapamycin
treatment alleviated sepsis-induced cardiac dysfunction via the
induction of autophagy (Hsieh et al., 2011). Inhibition of mTOR
by everolimus prevents left ventricular remodeling and limits
infarct size by inducing autophagy (Hsieh et al., 2011). These
studies support the present results showing the protective effect
of rapamycin on cardiac hypertrophy mediated by autophagy
induction.
In the present study, MEK inhibition reversed the effects
of rapamycin on the induction of autophagy and attenuation
of PE-induced cardiac hypertrophy, suggesting that rapamycin
protects against cardiac hypertrophy by inducing ERK dependent
autophagy. These results were confirmed in in vivo experiments,
which showed the attenuation of cardiac hypertrophy by
rapamycin in a MEK/ERK signaling dependent manner. ERK1/2
is among many proteins known to be involved in the regulation
of autophagy together with mTOR, AMPK, BH3-only proteins
such as Noxa and Beclin-1, and the p62 adaptor protein that
binds to LC3(Levine and Kroemer, 2008). Activation of the ERK
pathway by curcumin induces autophagy and inhibits the growth
of malignant glioma cells (Dong et al., 2015). Activation of the
MEK/ERK signaling pathway was shown to trigger autophagy by
modulating the expression of Beclin-1 through the dissociation
of mTOR complexes 1 and/or 2 in a study that suggested
that the protective or destructive roles of autophagy depend
on the MEK/ERK-regulated level of Beclin-1 expression (Wang
et al., 2009). Noxa is up-regulated by MEK/ERK signaling and
plays an important role in autophagy regulation. In melanoma
cells, Noxa is up-regulated by oncogenic activation of the
MEK/ERK pathway in correlation with constitutive activation
of autophagy (Liu et al., 2014). Our co-immunoprecipitation
results showed that Mcl-1 interacted with Beclin-1 only in the
absence of Noxa, suggesting that Noxa expression suppresses the
inhibition of Beclin-1 by Mcl-1 and thus promotes autophagy.
PE suppressed Noxa expression, and rapamycin up-regulated
Noxa via activation of MEK/ERK signaling. These results suggest
that autophagy dysregulation in cardiac hypertrophy could be
mediated by the down-regulation of Noxa.Further experiments
analyzing the effect of Noxa overexpression are necessary to
confirm this hypothesis.
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FIGURE 8 | Schematic illustration of the pathway of autophagy
induction by rapamycin in cardiomyocytes. Rapamycin treatment
activates the MEK/ERK signaling pathway, promoting the expression of
Beclin-1 and Noxa. Noxa suppressed the inhibitory effect of Mcl-1 on Beclin-1
resulting in the induction of autophagy.
In the present study, silencing of Beclin-1 suppressed
rapamycin-induced autophagy. Beclin-1 interacts with
antiapoptotic Bcl-2 family proteins, and the functional and
physical interaction between Beclin-1 and Bcl-2 is considered
important in the crosstalk between autophagy and apoptosis
(Pattingre et al., 2005; Nishida et al., 2008). Bcl-2 inhibits
Beclin-1 dependent autophagy, and ectopic expression of cardiac
Bcl-2 inhibits autophagy in the murine heart by interfering with
the formation of the Beclin-1/PI3K complex. The interaction
between Bcl-2 and Beclin-1 involves the BH3 domain of Beclin-1,
and disruption of this interaction increases autophagy (Maiuri
et al., 2007). Overexpression of Beclin-1 stimulates autophagy,
and this effect is reversed by Bcl-2 overexpression (Pattingre et al.,
2005). These studies are among many exploring the importance
of the balance between autophagy and apoptosis in disease.
Given the present results showing that the cardioprotective effect
of rapamycin is mediated by a MEK/ERK/Beclin-1 axis, it would
be of interest to examine the role of apoptosis in our model in
future studies.
Dysregulation of autophagy has been demonstrated in
cardiovascular disease as well as other diseases, and several
FDA-approved drugs induce autophagy, suggesting that
targeting autophagy is a potential strategy for the treatment of
cardiovascular diseases. Induction of hypertrophy suppresses
autophagy, and knockdown of autophagic genes such as Atg5
and Atg7 induces cardiomyocyte hypertrophy (Nakai et al.,
2007). Furthermore, induction of autophagy by rapamycin
suppresses cardiac hypertrophy in mice (Shioi et al., 2003;
Mcmullen et al., 2004). On the other hand, the role of autophagy
in ischemia-reperfusion (I-R) injury and heart failure is
controversial. While ablation of the proautophagic gene Beclin-1
prevents I-R induced cardiomyocyte death in mice (Matsui
et al., 2007), other studies showed that enhancing autophagy
through Beclin-1 overexpression has a protective effect against
I-R injury (Hamacher-Brady et al., 2006). The protective role of
autophagy was supported by studies showing that rapamycin
treatment had a cardioprotective role in a mouse model of I-R
injury (Khan et al., 2006). Therapeutic modulation of autophagy
has been used for the treatment of cardiovascular disorders,
and certain cardiovascular drugs such as β-receptor agonists
and β-receptor blockers modulate autophagy, although their
mechanism of action in inducing autophagy needs to be better
understood to harness their beneficial effects. Rapamycin-
based drugs, which induce autophagy, are used to prevent
restenosis after angioplasty; however, these drugs also lead to
the inhibition of endothelial cell repair (Grube and Buellesfeld,
2004; Hayashi et al., 2009). Here, we showed that rapamycin had
a protective effect against cardiac hypertrophy and elucidated a
potential underlying mechanism mediated by the induction of
autophagy via MEK/ERK dependent up-regulation of Beclin-1
and Noxa. Our results suggest that the cardioprotective effects
of rapamycin-mediated autophagy induction could be used in
the treatment of other cardiovascular disorders and thus merit
further investigation.
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